Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corticosteroids + rivaroxaban
- Development stage
- Phase 3
- Lead developer
- University of British Columbia
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
This represents a combination of corticosteroids (a class of anti-inflammatory medications) and rivaroxaban (an anticoagulant). This is not a formulated combination product but rather describes the concurrent use of these medications. Studies suggest that prednisone (a corticosteroid) administration has no apparent influence on the anticoagulant effects of rivaroxaban in healthy dogs, suggesting that combined therapy would not require dosage adjustments. However, comprehensive human data on this combination is limited.
02
Targets
F10 (Factor Xa)
Beyond the preview
Go deeper on corticosteroids + rivaroxaban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corticosteroids + rivaroxaban.